scholarly journals Baculoviral vector loaded mesenchymal stem cells as efficient gene therapy tools for cancer treatment

2016 ◽  
Vol 40 ◽  
pp. 1121-1128
Author(s):  
Sedef Hande AKTAŞ ◽  
Hakan AKBULUT ◽  
Ayşe Eser ELÇİN ◽  
Mahmut PARMAKSIZ ◽  
Arzu Aktan KESKİN ◽  
...  
2021 ◽  
Vol 21 ◽  
Author(s):  
Wenhua He ◽  
Qingxuan Li ◽  
Yan Lu ◽  
Dingyue Ju ◽  
Yu Gu ◽  
...  

Background: Cancer, a malignant tumor, is caused by the failure of the mechanism that controls cell growth and proliferation. Late clinical symptoms often manifest as lumps, pain, ulcers, and bleeding. Systemic symptoms include weight loss, fatigue, and loss of appetite. It is a major disease that threatens human life and health. How to treat cancer is a long-standing problem that needs to be overcome in the history of medicine. Discussion: In the text, we systematically review the cancer treatment evolution from traditional methods to novel approaches that include immunotherapy, nanotherapy, stem cell theapy, and gene therapy. We provide the latest review of the application status, clinical trials and development prospects of mesenchymal stem cells and gene therapy for cancer, as well as their integration in cancer treatment. Mesenchymal stem cells are effective carriers carrying genes and provide new clinical ideas for tumor treatment. Conclusion: This review focuses on the current status, application prospects and challenges of mesenchymal stem cell combined gene therapy for cancer, and provides new ideas for clinical research.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 843
Author(s):  
Noha Attia ◽  
Mohamed Mashal ◽  
Gustavo Puras ◽  
Jose Luis Pedraz

The cell-based approach in gene therapy arises as a promising strategy to provide safe, targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism, mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses, optimization for clinical use is an ongoing challenge. On the way of improvement, genetically modified MSCs have been combined with various novel techniques and tools (e.g., exosomes, spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine.


2004 ◽  
Vol 171 (4S) ◽  
pp. 373-373
Author(s):  
Trinity J. Bivalacqua ◽  
Mustafa F. Usta ◽  
Hunter C. Champion ◽  
Weiwen Deng ◽  
Philip J. Kadowitz ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Ameneh Jafari ◽  
Mostafa Rezaei-Tavirani ◽  
Behrouz Farhadihosseinabadi ◽  
Hakimeh Zali ◽  
Hassan Niknejad

AbstractCancer is a leading cause of death in both developed and developing countries, and because of population growth and aging, it is a growing medical burden worldwide. With robust development in medicine, the use of stem cells has opened new treatment modalities in cancer therapy. In adult stem cells, mesenchymal stem cells (MSCs) are showing rising promise in cancer treatment due to their unique properties. Among different sources of MSCs, human amniotic fluid/membrane is an attractive and suitable reservoir. There are conflicting opinions about the role of human amniotic membrane/fluid mesenchymal stem cells (hAMSCS/hAFMSCs) in cancer, as some studies demonstrating the anticancer effects of these cells and others suggesting their progressive effects on cancer. This review focuses on recent findings about the role of hAMSCs/hAFMSCs in cancer treatment and summarizes the suppressing as well as promoting effects of these cells on cancer progression and underling mechanisms.


2002 ◽  
Vol 8 (21) ◽  
pp. 1917-1928 ◽  
Author(s):  
G. Pelled ◽  
G. Turgeman ◽  
H. Aslan ◽  
Z. Gazit ◽  
D. Gazit

Small ◽  
2011 ◽  
Vol 8 (3) ◽  
pp. 441-451 ◽  
Author(s):  
Wen-Wen Deng ◽  
Xia Cao ◽  
Miao Wang ◽  
Yan Yang ◽  
Wei-Yan Su ◽  
...  

2011 ◽  
Vol 22 (6) ◽  
pp. 733-743 ◽  
Author(s):  
Chung Heon Ryu ◽  
Sang-Hoon Park ◽  
Soon A Park ◽  
Seong Muk Kim ◽  
Jung Yeon Lim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document